PMID- 12455047 OWN - NLM STAT- MEDLINE DCOM- 20030106 LR - 20220330 IS - 0020-7136 (Print) IS - 0020-7136 (Linking) VI - 103 IP - 1 DP - 2003 Jan 1 TI - Polycyclic aromatic hydrocarbon-inducible DNA adducts: evidence by 32P-postlabeling and use of knockout mice for Ah receptor-independent mechanisms of metabolic activation in vivo. PG - 5-11 AB - There is significant human exposure to polycyclic aromatic hydrocarbons (PAHs), many of which are potent carcinogens in laboratory animals and are suspected human carcinogens. The PAHs are bioactivated by cytochrome P450 (CYP)1A1/1B1 enzymes to reactive intermediates that bind to DNA, a critical step in the initiation of carcinogenesis. The Ah receptor (AHR) plays a critical role in the induction of CYP1 enzymes (i.e., CYP1A1, 1A2 and 1B1) by PAHs such as benzo[a]pyrene (BP) and 3-methylcholanthrene (MC). In our investigation, we tested the hypothesis that AHR-null animals are less susceptible to PAH-induced DNA adduct formation than wild-type animals. Wild-type [AHR (+/+)] mice or mice lacking the gene for the AHR were treated with a single dose (100 micromol/kg) of BP or MC, and hepatic DNA adducts were analyzed by (32)P-postlabeling. BP induced multiple hepatic DNA adducts in wild-type as well as AHR-null animals, suggesting the existence of AHR-independent mechanisms for BP metabolic activation. On the other hand, DNA adduct formation was markedly suppressed in AHR-null animals exposed to MC, although the major MC-DNA adduct was produced in these animals. Hepatic activities and apoprotein contents of 7-ethoxyresorufin O-deethylase (EROD) (CYP1A1) and 7-methoxyresorufin O-demethylase (MROD) (CYP1A2) activities were markedly induced by BP and MC in the wild-type, but not, in AHR-null animals. CYP1B1 expression was also induced, albeit to a lesser extent by the PAH MC, but not BP, in the wild-type animals. In conclusion, these results demonstrate the existence of AHR- and CYP1A1-independent mechanisms of PAH metabolic activation in mouse liver, a phenomenon that may have important implications for PAH-mediated carcinogenesis. CI - Copyright 2002 Wiley-Liss, Inc. FAU - Kondraganti, Sudha R AU - Kondraganti SR AD - Department of Pediatrics, Baylor College of Medicine, Houston, TX 77030, USA. FAU - Fernandez-Salguero, Pedro AU - Fernandez-Salguero P FAU - Gonzalez, Frank J AU - Gonzalez FJ FAU - Ramos, Kenneth S AU - Ramos KS FAU - Jiang, Weiwu AU - Jiang W FAU - Moorthy, Bhagavatula AU - Moorthy B LA - eng GR - ES 09132/ES/NIEHS NIH HHS/United States PT - Comparative Study PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Research Support, U.S. Gov't, P.H.S. PL - United States TA - Int J Cancer JT - International journal of cancer JID - 0042124 RN - 0 (DNA Adducts) RN - 0 (Phosphorus Isotopes) RN - 0 (Polycyclic Aromatic Hydrocarbons) RN - 0 (Receptors, Aryl Hydrocarbon) RN - 0 (polycyclic aromatic hydrocarbons-DNA adduct) RN - 3417WMA06D (Benzo(a)pyrene) RN - 56-49-5 (Methylcholanthrene) RN - 9007-49-2 (DNA) RN - EC 1.14.14.1 (Aryl Hydrocarbon Hydroxylases) RN - EC 1.14.14.1 (CYP1B1 protein, human) RN - EC 1.14.14.1 (Cyp1b1 protein, mouse) RN - EC 1.14.14.1 (Cytochrome P-450 CYP1A1) RN - EC 1.14.14.1 (Cytochrome P-450 CYP1A2) RN - EC 1.14.14.1 (Cytochrome P-450 CYP1B1) SB - IM MH - Animals MH - Aryl Hydrocarbon Hydroxylases/*metabolism MH - Benzo(a)pyrene/toxicity MH - Cytochrome P-450 CYP1A1/*metabolism MH - Cytochrome P-450 CYP1A2/*metabolism MH - Cytochrome P-450 CYP1B1 MH - DNA/*drug effects/metabolism MH - DNA Adducts/*metabolism MH - Enzyme Activation MH - Enzyme Induction MH - Homozygote MH - Isotope Labeling MH - Liver/*drug effects/enzymology MH - Male MH - Methylcholanthrene/toxicity MH - Mice MH - Mice, Inbred C57BL MH - Mice, Knockout MH - Microsomes, Liver/enzymology MH - Phosphorus Isotopes MH - Polycyclic Aromatic Hydrocarbons/*metabolism MH - Receptors, Aryl Hydrocarbon/*metabolism EDAT- 2002/11/28 04:00 MHDA- 2003/01/08 04:00 CRDT- 2002/11/28 04:00 PHST- 2002/11/28 04:00 [pubmed] PHST- 2003/01/08 04:00 [medline] PHST- 2002/11/28 04:00 [entrez] AID - 10.1002/ijc.10784 [doi] PST - ppublish SO - Int J Cancer. 2003 Jan 1;103(1):5-11. doi: 10.1002/ijc.10784.